Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more
Vetoquinol (VETO) - Total Liabilities
Latest total liabilities as of June 2025: €158.29 Million EUR
Based on the latest financial reports, Vetoquinol (VETO) has total liabilities worth €158.29 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vetoquinol - Total Liabilities Trend (2004–2024)
This chart illustrates how Vetoquinol's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vetoquinol Competitors by Total Liabilities
The table below lists competitors of Vetoquinol ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Target Hospitality Corp
NASDAQ:TH
|
USA | $138.91 Million |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
|
China | CN¥258.97 Million |
|
V2 Retail Limited
NSE:V2RETAIL
|
India | ₹20.00 Billion |
|
Site Centers Corp
NYSE:SITC
|
USA | $83.97 Million |
|
Xiamen Sunrise Wheel Group Co Ltd
SHE:002593
|
China | CN¥2.27 Billion |
|
Suzhou YourBest New-type Materials Co.Ltd.
SHE:301266
|
China | CN¥1.80 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Vetoquinol's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vetoquinol's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vetoquinol (2004–2024)
The table below shows the annual total liabilities of Vetoquinol from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €168.20 Million | +1.86% |
| 2023-12-31 | €165.12 Million | -1.23% |
| 2022-12-31 | €167.19 Million | -8.75% |
| 2021-12-31 | €183.21 Million | -33.20% |
| 2020-12-31 | €274.26 Million | +118.56% |
| 2019-12-31 | €125.49 Million | +22.43% |
| 2018-12-31 | €102.50 Million | -5.31% |
| 2017-12-31 | €108.24 Million | -11.78% |
| 2016-12-31 | €122.70 Million | -0.23% |
| 2015-12-31 | €122.98 Million | -18.54% |
| 2014-12-31 | €150.97 Million | +30.28% |
| 2013-12-31 | €115.88 Million | -9.77% |
| 2012-12-31 | €128.43 Million | +20.00% |
| 2011-12-31 | €107.02 Million | -14.50% |
| 2010-12-31 | €125.18 Million | -2.75% |
| 2009-12-31 | €128.72 Million | +29.53% |
| 2008-12-31 | €99.38 Million | -1.15% |
| 2007-12-31 | €100.53 Million | +1.06% |
| 2006-12-31 | €99.47 Million | -11.89% |
| 2005-12-31 | €112.90 Million | +6.93% |
| 2004-12-31 | €105.58 Million | -- |